NERV
NASDAQMinerva Neurosciences Inc
Minerva Neurosciences Inc (NERV) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for NERV, including 3 press releases and news items, 2 SEC filings and 1 insider trade. The most recent was published Nov 6, 2026.
NERV rankings
Financial highlights
Full financials- Net income, TTM
- -$290.86M
- Cash
- $20.22M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks30+100%
2026-05-172026-11-08
Mix1290d
- Other6(50%)
- Insider3(25%)
- SEC Filings2(17%)
- Analyst1(8%)
Activity · 52 weeks8546 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Minerva Neurosciences Inc10-Q - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences Provides Third Quarter 2026 Financial Results and Business UpdatesConfirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and to improve clinical trial methodology for negative symptoms Roluperidone remains the only late-stage drug candidate for this high-need population Company to host in-person and virtual KOL event on November 12, 2026 at 10:00 AM ET BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today
- INSIDERDirector Kaul Inderjit was granted 2,328 stock options (SEC Form 4)4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- PRMinerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in LondonBURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in the 2026 Jefferies Global Healthcare Conference in London. 2026 Jefferies Global Healthcare ConferenceDates: Monday, November 16 & Tuesday, November 17, 2026 Format: Fireside chat and 1x1 meetingsFireside Chat: Monday, November 16, 2026 from 4:00 – 4:25 p.m. GMT Location: London, UK If you are interested in meeting with the Minerva team during the conference, please reach out to your respective Jefferies representative
- PRMinerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of SchizophreniaBURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host an in-person and virtual event in New York on Thursday, November 12, 2026, at 10:00 AM ET featuring several key opinion leaders and company management focused on the opportunity for roluperidone in treating the negative symptoms of schizophrenia. For more details and to register for the event, click here. The event will feature three leading experts in negative symptoms of schizophrenia, Christoph Correll, MD (Donald and Barbara Zucker S
- PRMinerva Neurosciences to Participate in Two Upcoming Investor ConferencesBURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences. Wells Fargo Healthcare ConferenceDate: Tuesday, September 8Format: 1x1 meetingsLocation: New York, NY 2026 Cantor Global Healthcare ConferenceDate: Wednesday, September 9Format: Fireside chat and 1x1 meetingsTime: 2:45 – 3:15 PM EDTLocation: New York, NY
- INSIDERNew insider Reilly Joseph H. claimed ownership of 20,872 shares (SEC Form 3)3 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERNew insider Aliquo Anthony claimed ownership of 1,683 shares (SEC Form 3)3 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- ANALYSTMinerva Neurosciences upgraded by Jefferies with a new price targetJefferies upgraded Minerva Neurosciences from Hold to Buy and set a new price target of $10.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences IncSCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences IncSCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECSEC Form 8-K filed by Minerva Neurosciences Inc8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form 10-Q filed by Minerva Neurosciences Inc10-Q - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences Provides Second Quarter 2026 Financial Results and Business UpdatesConfirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the confirmatory Phase 3 trial of roluperidone Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported financial and business updates for the second quarter ended June 30, 2026. "The psychiatry field has increasing
- INSIDERSEC Form 4 filed by Director Kaul Inderjit4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences IncSCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)
- INSIDERSEC Form 4 filed by CEO Luthringer Remy4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Laghrissi-Thode Fouzia4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by SVP, CFO and Secretary Ahlholm Frederick W4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Kupfer David4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Hasler Hans Peter4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Van Heek G Jan4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Kaul Inderjit4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
NERV FAQ
10 questionsWhat does Minerva Neurosciences Inc do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import...What is the latest news on NERV?
In the last 30 days Quantisnow tracked 6 wire items for NERV: 3 press releases and news items, 2 SEC filings and 1 insider trade. The most recent was published on November 6, 2026.Is NERV profitable?
No. Minerva Neurosciences Inc reported a net loss of $290.86M for the twelve months ended Sep 30, 2026.How much cash and debt does NERV have?
Minerva Neurosciences Inc reported $20.22M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NERV stock trade?
Minerva Neurosciences Inc (NERV) is listed on NASDAQ.What sector and industry is NERV in?
Minerva Neurosciences Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Minerva Neurosciences Inc go public?
Minerva Neurosciences Inc (NERV) completed its IPO in 2014.What are analysts saying about NERV?
Across the last 3 analyst actions on Minerva Neurosciences Inc, there was 1 upgrade and 0 downgrades. The most recent action was from Jefferies: Buy with a $10.00 price target on 2026-08-14. Recent price targets range from $5.00 to $14.00.What companies are similar to NERV?
Notable peers in the same industry include ACAD (ACADIA Pharmaceuticals Inc.), ALKS (Alkermes plc), NBIX (Neurocrine Biosciences Inc.), AXSM (Axsome Therapeutics Inc.). Compare NERV side-by-side with any of them on Quantisnow.How can I track NERV on Quantisnow?
Quantisnow aggregates Minerva Neurosciences Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NERV to receive live email and push alerts on every new disclosure.